文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

低氧性呼吸衰竭患者自主觉醒试验后首次压力支持通气转换失败:COVID-19的影响

Failure of First Transition to Pressure Support Ventilation After Spontaneous Awakening Trials in Hypoxemic Respiratory Failure: Influence of COVID-19.
PubMed 文献 · Crit Care Explor · 2023-08-25
一句话结论低氧性呼吸衰竭患者自主觉醒试验后首次压力支持通气转换失败率为43.7%,COVID-19患者更高(49.7% vs 30.5%),失败与更差预后相关。

这项回顾性队列研究在阿根廷一家私立医院28张床位的综合ICU进行,纳入274例不同病因的低氧性呼吸衰竭(PaO2/FiO2<300 mmHg)接受控制性机械通气的患者,其中COVID-19 189例、非COVID-19 85例。首次压力支持通气转换失败定义为PSV开始后3个日历日内需返回完全控制性机械通气,总失败率为43.7%(120/274),COVID-19组高于非COVID-19组(49.7% vs 30.5%,p=0.003)。多因素分析显示COVID-19诊断(OR 2.22,95%CI 1.15-4.43,p=0.020)、既往使用神经肌肉阻滞剂(OR 2.16,95%CI 1.15-4.11,p=0.017)和较高芬太尼剂量(OR 1.29,95%CI 1.05-1.60,p=0.018)增加失败风险,较高BMI(OR 0.95,95%CI 0.91-0.99,p=0.029)、PaO2/FiO2(OR 0.87,95%CI 0.78-0.97,p=0.017)和pH(OR 0.61,95%CI 0.38-0.96,p=0.035)具有保护作用。失败组60天呼吸机依赖(p<0.001)、机械通气时长(p<0.0001)和ICU停留时间(p=0.001)更高,COVID-19组失败者死亡率更高(p<0.001),非COVID-19组无显著差异(p=0.083)。

要点

  • 低氧性呼吸衰竭患者SAT后首次PSV转换失败率43.7%(120/274),COVID-19组49.7%高于非COVID-19组30.5%(p=0.003)。
  • COVID-19诊断(OR 2.22,95%CI 1.15-4.43,p=0.020)、既往神经肌肉阻滞剂(OR 2.16,95%CI 1.15-4.11,p=0.017)和较高芬太尼剂量(OR 1.29,95%CI 1.05-1.60,p=0.018)独立增加首次PSV失败风险。
  • 较高BMI(OR 0.95,95%CI 0.91-0.99,p=0.029)、PaO2/FiO2(OR 0.87,95%CI 0.78-0.97,p=0.017)和pH(OR 0.61,95%CI 0.38-0.96,p=0.035)为保护因素。
  • PSV转换失败与60天呼吸机依赖(p<0.001)、机械通气时长(p<0.0001)和ICU停留时间(p=0.001)增加相关。
  • COVID-19组中失败者死亡率更高(p<0.001),非COVID-19组无显著差异(p=0.083)。

适用人群与场景

  • 不同病因的低氧性呼吸衰竭患者,动脉血氧分压/吸入氧浓度(PaO2/FiO2)<300 mmHg,接受控制性机械通气。
  • 阿根廷一家私立医院28张床位的综合ICU,COVID-19患者189例,非COVID-19患者85例。

诊断标准与关键阈值

  • 低氧性呼吸衰竭定义:PaO2/FiO2 < 300 mmHg。
  • 首次PSV转换失败定义:PSV开始后3个日历日内需返回完全控制性机械通气。

研究设计与关键结果

  • 研究类型:回顾性队列研究,单中心(28张床位的综合ICU),纳入274例低氧性呼吸衰竭患者(COVID-19 189例,非COVID-19 85例)。
  • 干预与对照:无干预;比较COVID-19与非COVID-19患者首次PSV转换失败率。
  • 主要终点:首次PSV转换失败率43.7%(120/274),COVID-19组49.7% vs 非COVID-19组30.5%(p=0.003)。
  • 独立危险因素:COVID-19诊断(OR 2.22,95%CI 1.15-4.43,p=0.020)、既往神经肌肉阻滞剂(OR 2.16,95%CI 1.15-4.11,p=0.017)、较高芬太尼剂量(OR 1.29,95%CI 1.05-1.60,p=0.018)。
  • 保护因素:较高BMI(OR 0.95,95%CI 0.91-0.99,p=0.029)、PaO2/FiO2(OR 0.87,95%CI 0.78-0.97,p=0.017)、pH(OR 0.61,95%CI 0.38-0.96,p=0.035)。
  • 失败组与非失败组比较:60天呼吸机依赖(p<0.001)、机械通气时长(p<0.0001)、ICU停留时间(p=0.001)更高。
  • 死亡率:COVID-19组失败者死亡率更高(p<0.001),非COVID-19组无显著差异(p=0.083)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于低氧性呼吸衰竭患者,尤其是COVID-19、既往使用神经肌肉阻滞剂或芬太尼剂量较高者,SAT后首次PSV转换失败风险较高,临床需警惕并加强监测。
  • 较高的BMI、PaO2/FiO2和pH与较低的转换失败风险相关,在评估拔管/切换模式时可参考这些因素。
  • 转换失败与更差的预后(60天呼吸机依赖、机械通气时长、ICU停留时间增加,COVID-19组死亡率更高)相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To describe the rate of failure of the first transition to pressure support ventilation (PSV) after systematic spontaneous awakening trials (SATs) in patients with acute hypoxemic respiratory failure (AHRF) and to assess whether the failure is higher in COVID-19 compared with AHRF of other etiologies. To determine predictors and potential association of failure with outcomes.

DESIGN: Retrospective cohort study.

SETTING: Twenty-eight-bedded medical-surgical ICU in a private hospital (Argentina).

PATIENTS: Subjects with arterial pressure of oxygen (AHRF to Fio2 [Pao2/Fio2] < 300 mm Hg) of different etiologies under controlled mechanical ventilation (MV).

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: We collected data during controlled ventilation within 24 hours before SAT followed by the first PSV transition. Failure was defined as the need to return to fully controlled MV within 3 calendar days of PSV start. A total of 274 patients with AHRF (189 COVID-19 and 85 non-COVID-19) were included. The failure occurred in 120 of 274 subjects (43.7%) and was higher in COVID-19 versus non-COVID-19 (49.7% and 30.5%; p = 0.003). COVID-19 diagnosis (odds ratio [OR]: 2.22; 95% CI [1.15-4.43]; p = 0.020), previous neuromuscular blockers (OR: 2.16; 95% CI [1.15-4.11]; p = 0.017) and higher fentanyl dose (OR: 1.29; 95% CI [1.05-1.60]; p = 0.018) increased the failure chances. Higher BMI (OR: 0.95; 95% CI [0.91-0.99]; p = 0.029), Pao2/Fio2 (OR: 0.87; 95% CI [0.78-0.97]; p = 0.017), and pH (OR: 0.61; 95% CI [0.38-0.96]; p = 0.035) were protective. Failure groups had higher 60-day ventilator dependence (p < 0.001), MV duration (p < 0.0001), and ICU stay (p = 0.001). Patients who failed had higher mortality in COVID-19 group (p < 0.001) but not in the non-COVID-19 (p = 0.083).

CONCLUSIONS: In patients with AHRF of different etiologies, the failure of the first PSV attempt was 43.7%, and at a higher rate in COVID-19. Independent risk factors included COVID-19 diagnosis, fentanyl dose, previous neuromuscular blockers, acidosis and hypoxemia preceding SAT, whereas higher BMI was protective. Failure was associated with worse outcomes.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Pérez J, Accoce M, Dorado JH, et al. Failure of First Transition to Pressure Support Ventilation After Spontaneous Awakening Trials in Hypoxemic Respiratory Failure: Influence of COVID-19. Crit Care Explor. 2023. PMID: 37644972. doi:10.1097/CCE.0000000000000968

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。